Today mAbsolve along with collaborators at RIC and Protein Stable, published a peer-reviewed article analysing over 70 different Fc silencing variants that have been reported in the literature. This by far the most comprehensive analysis of silencing variants ever reported. mAbsolve’s STR mutations are included in this report and are identified as superior based on … Read more
The Nonhuman Primate Reagent Resource (NHPRR), part of the University of Massachusetts Medical School, and mAbsolve, developers of a novel Fc silencing variant, today announced a licensing deal for mAbsolve’s Fc silencing technology. The full press release is available in the PDF below.
mAbsolve CEO has today published a review on the history of antibody Fc silencing. This covers Geoff’s personal experiences and insights with silencing over his career. A must read for anybody interested in Fc silencing and therapeutic antibody history in general.
mAbsolve has now had patents for the STR silencing mutations granted in the United States (US12037380B2), Canada (CA3179582), United Kingdom (GB2595299B), Australia (AU2021277578B2) and Japan (JP7434609B2). We continue to push forward with our applications in other territories and expect these to be awarded in due course.
Antibody Solutions have licensed our STR technology to provide their clients with access to this cutting edge technology during their discovery campaigns. See the full press release below for more details.
mAbsolve will be exhibiting at the Festival of Biologics in Basel on the 10-12th of October. We will be located in the startup zone will also have a poster with a more detailed description of our technology in the poster area. Please do come along and chat with us to understand how we can help … Read more
The Medical and Healthcare products Regulatory Agency (MHRA) has licensed mAbsolves novel Fc silencing technology to produce gold standard negative controls for Fc receptor binding assays. The full press release is below.
OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to the STR technology for antibodies that have been generated using OmniAb’s antibody discovery platform. For the full press release please see the PDF below.
Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in Amsterdam. Geoff will be talking about the diversity of antibody formats and modiciations utilised in the clinic and in particular focussing on Fc silencing and the work mAbsolve has done to compare it’s STR silencing mutations with … Read more
Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University have reported on the design of an ultra-high affinity ACE2 variant that has been coupled to an Fc domain incorporating mAbsolve’s STR mutations for silencing and the YTE mutations for half-life extension. It is hoped that this … Read more